ISSN 1180-4882
3 papers in the library · 25 citations · publishing 2003-2024
Journal of Psychiatry and Neuroscience June 1, 2022 Stephanie L. Borgland, Drew M. Neyens 14 citations
Private clinics and registered clinical trials using serotonergic psychedelics for psychiatric conditions such as substance use disorder and major depressive disorder have grown substantially. Classical psychedelics include lysergic acid diethylamide.
Journal of Psychiatry and Neuroscience September 19, 2024 Gabriella Gobbi 7 citations
Psychedelics like psilocybin and LSD primarily activate serotonin 5-HT2A receptors but also affect other receptors and neural circuits, fostering transformative cognitive and mystical experiences. Unlike conventional psychiatric drugs, they influence brain networks such as the default mode network and the cortico–striato–thalamo–cortical network, and involve molecular mechanisms including neuroplasticity and epigenetics. This review argues that psychedelics' complex actions require a new conceptual framework in psychiatry to integrate brain, mind, and spirituality, and to avoid oversimplification when studying their therapeutic potential for mental disorders.
Journal of Psychiatry and Neuroscience July 1, 2003 Ronald T. Coutts 4 citations
This 428-page book reviews psychoactive plants, organized into 10 chapters covering stimulants, cognitive enhancers, sedatives, psychotherapeutic herbs, analgesics, hallucinogens, and cannabis. Each plant is discussed under consistent headings: history, botany, chemical constituents, mechanisms of action, pharmacokinetics, toxicity, and general effects. The text provides definitions and introduces neuroscientific and pharmacological concepts, with extensive references. However, many chemical structures contain errors, such as misnamed compounds and omitted bonds, which detract from the otherwise useful introductory resource.